Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRODIGE 22-ECKINOXE : Randomized Phase II Trial of Neoadjuvant FOLFOX 4 Versus FOLFOX 4 With Cetuximab Versus Immediate Surgery in Locally Advanced Colon Cancer

NCT01675999 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT01675999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01675999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRODIGE 22-ECKINOXE : Randomized Phase II Trial of Neoadjuvant FOLFOX 4 Versus FOLFOX 4 With Cetuximab Versus Immediate Surgery in Locally Advanced Colon Cancer
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2012
Completion date
February 28, 2021
Enrollment
186 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, locally advanced malignant neoplasm